Richter Gedeon Vegyeszeti Gyar Rt

Richter Gedeon Vlcyeszeti Gyar Rt.

Richter Gedeon Nyrt.

Istvan Laszlovszky

Bela Kiss

Laszlo Szporny

Erzsebet Lapis

Eva Palosi

Dora Groo

Egon Karpati

Edit Toth

Zsolt Szombathelyi

Jozsef Torley

Katalin Csomor

Judit Laszy

Ferenc Auth

Csaba Szantay

Sandor Gorog

Tibor Keve

Bela Stefko

Ferenc Trischler

Janos Galambos

Istvan Hajdu

Aniko Gere

Adam Sarkadi

Gabor Megyeri

Laszlo Gaal

Bela Hegedus

Erik Bogsch

Lilla Forgacs

Mihaly Bodo

Csaba Kuthi

Zsolt Szentirmay

Gyoergy Andor

Gyoergy Nemeth

Lajos Szabo

Gyorgy Kalaus

Istvan Gyertyan

Katalin Saghy

Gyorgy Domany

Eva Againe Csongor

Janos Fischer

Sandor Szabo

Katalin Nogradi

Lajos Kovacs

Laszlo Dobay

Bela Molnar

Tamas Fodor

Tibor Acs

Istvan Vago

Maria Incze

Karoly Nador

Ferenc Soti

Gyorgy Ferenczy

Margit Pellioniszne Paroczai

Zsuzsanna Balogh Nee Kardos

Anna Kassai Nee Zieger

Jozsef Turley

Laszlo Haal

Jozef Torley

Groo

Pal Scheiber

Monika Csejtei

Nee Szelecsenyi Andrasi

Feranc Auth

Eszter Thuroczyne Kalman

Anna Kassainee Zieger

Bala Stefko

Anna Kassi Nee Zieger

Edith Toth

The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein Rand Rrepresent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or Rand Rmay form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.

(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists

2-methoxyphenylpiperazine derivatives

The invention relates to novel 2-oxo-1-oxa-8-azaspiro[4,5]decane derivatives of the formula (I), ##STR1## wherein X means oxygen or an &gt;NR group, wherein

2-oxo-1-oxa-8 azaspiro[4,5]decane derivatives, pharmaceutical

The invention relates to, therapeutically active 2-oxo-3,8-diazaspiro[4,5]decane derivatives (I), ##STR1## wherein R means hydrogen, a C.sub.1-12 alkyl, C.sub.3-6 cycloalkyl, carbocyclic C.sub.6-10 aryl or carbocyclic C.sub.6-10 aryl-C.sub.1-4 alkyl group, the latter two optionally being substituted on their aromatic moiety by one or more, same or different halogen(s) or one or more C.sub.1-4 alkyl or C.sub.1-4 alkoxy group(s);

2-oxo-3,8-diazaspiro(4,5)decane derivatives, pharmaceutical compositions

The invention relates to novel, therapeutically active 4-methylene-2-oxo-8-azaspiro[4,5]decane derivatives of the compound, ##STR1## wherein X means oxygen or an &gt;NR group, wherein

4-methylene-2-oxo-8-azaspiro[4,5]decane derivatives, pharmaceutical

The invention relates to novel compounds 1-oxa-2-oxo-8- of the formula (I), ##STR1## wherein X means oxygen or an &gt;NR group, wherein

1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives, pharmaceutical

The invention relates to novel, therapeutically active 4,4-disubstituted piperidine derivatives of the formula (I), ##STR1## wherein R.sup.1 means hydrogen or --CONHR group, wherein

4,4-disubstituted piperidine derivatives, pharmaceutical compositions

The invention relates to novel nitrogen- and sulfur-containing heterocyclic compounds of the formula (I), acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the formula (I) ##STR1## Ar stands for an optionally mono- or polysubstituted aryl or heteroaryl group;

Heterocyclic compounds containing nitrogen and sulfur, pharmaceutical

The invention relates to novel 1,4-disubstituted piperazine derivatives of the general formula (I), pharmaceutically acceptable acid addition and quaternary ammonium salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are the same or different and stand for hydrogen or halogen or a trihalomethyl, lower alkyl, lower alkoxy, nitro, hydroxyl, aralkyloxy or an 1-(2-propenyl-4-piperazinyl) group;

1,4-Disubstituted piperazines having dopaminergic activity

The invention relates to novel benzhydryl-piperazine derivatives of the general formula (I) and the acid addition and quaternary ammonium salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and stand for hydrogen or halogen, or a trihalomethyl, C.sub.1-4 alkyl or C.sub.1-4 alkoxy group;

Benzhydrylpiperazines pharmaceutical compositions thereof and method of

The invention relates to novel 1,4-disubstituted piperazine derivatives of the general formula (I), pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R.sub.1 and R.sub.2 are the same or different and stand for hydrogen or halogen or a lower alkyl, trihalomethyl or lower alkoxy group. The compounds of the general formula (I) are therapeutically useful for the treatment of diseases arising from a hypofunction of the dopaminergic system.

1,4-disubstituted piperazines, pharmaceutical compositions thereof and

The invention relates to novel 2-halogenated 8- and 1,8-substituted ergolene derivatives of the formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the formula (I) ##STR1## wherein X stands for a halogen;

2-Halogenated-8- and 1,8-substituted ergolenes

The invention relates to new racemic and optically active 1,12b-disubstituted octahydroindolo[2,3-a]quinolizine derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and represent hydrogen, halogen, nitro, alkyl having from 1 to 6 carbon atoms, alkoxy having from 1 to 6 carbon atoms or hydroxyl,

1,12-disubstituted octahydroindolo[2,3-]quinolizine derivatives,

The invention relates to the new (-)-1.beta.-ethyl-1.alpha.-hydroxymethyl-1,2, 3,4,6,7,12,12b.alpha.-octa-hydroindolo[2,3-a] quinolizine of the formula (I) ##STR1## and acid addition salts thereof. According to another aspect of the invention there is provided a process for the preparation of the compound of formula (I) and acid addition salts thereof by resolution of the corresponding racemic compound and optionally by subsequent hydrolysis and/or salt formation. The compound of formula (I) shows a remarkable peripheral vasodilating and antihypoxial activity. Pharmaceutical compositions comprising it as active ingredient are also within the scope of the invention.

(-)-1.beta.-ethyl-1.alpha.-hydroxymethyl-1,2,3,4,6,7,12,

The invention relates to a novel process for the preparation of partially new 2-halonicergoline derivatives of the formula (I), ##STR1## wherein X stands for chlorine, bromine or iodine atom, as well as their acid addition salts. The process of the invention comprises esterifying a novel 2-halo-1-methyllumilysergol of the formula (II), ##STR2## wherein X is the same as defined above, or an acid addition salt thereof and, if desired, converting the thus-obtained 2-halonicergoline derivative of the formula (I) to an acid addition salt. The compounds of the invention improve the cognitive function of the brain and show an antihypoxic as well as a strong .alpha.-adrenerg blocking and calcium-antagonistic action.

2-chloronicergoline having antihypoxic activity

Growing community of inventors

Budapest, Hungary

Istvan Laszlovszky